Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Reverse the HYpoTHyroid Status in Acute Myocardial InfarCtion (RHYTHMIC)

Conditions:   Myocardial Infarction;   Hypothyroidism
Intervention:   Drug: Levothyroxine
Sponsors:   Cardiovascular Institute & Fuwai Hospital;   Beijing Municipal Science & Technology Commission;   Peking Union Medical College Hospital;   Peking University Third Hospital;   Beijing Anzhen Hospital;   Beijing Chao Yang Hospital;   Beijing Friendship Hospital;   The Luhe Teaching Hospital of the Capital Medical University
Not yet recruiting - verified July 2015

Tomography Emission Positron Assessment of Endothelial Dysfunction With the Waning of a Heart Attack in Patients With Diabetes Type II

Condition:   Myocardial Infarction
Intervention:   Other: Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)
Sponsor:   University Hospital, Caen
Recruiting - verified July 2015

COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Device: Cooling + PCI;   Device: PCI only
Sponsor:   ZOLL Circulation, Inc., USA
Recruiting - verified July 2015

Myocardial Deformation in Real-time 3D Ultrasound. Normal Values in Adults and Validation Against the Tagged MRI

Condition:   Myocardial Infarction
Interventions:   Other: MRI;   Other: 3D cardiac ultrasound
Sponsor:   University Hospital, Caen
Recruiting - verified July 2015

Effects of Glucagon Like Peptide-1 on No-reflow

Condition:   Acute ST-segment Elevation Myocardial Infarction
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Chen Wei Ren, MD
Recruiting - verified July 2015

Follow-up of Patients Bound for PCI After Implementation of a Helicopter Emergency Medical System

Condition:   ST-elevation Myocardial Infarction
Intervention:   Other: Helicopter Emergency Medical Service
Sponsors:   Rigshospitalet, Denmark;   TrygFonden, Denmark
Active, not recruiting - verified July 2015

Novel Biomarkers of Thrombotic Risk

Condition:   Myocardial Infarction
Intervention:  
Sponsors:   University of Vermont;   Janssen Research & Development, LLC
Recruiting - verified July 2015

Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

Conditions:   Gastrointestinal Hemorrhage;   Cardiovascular Diseases
Intervention:  
Sponsors:   Population Health Research Institute;   Heart and Stroke Foundation of Ontario
Not yet recruiting - verified July 2015

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center (CPC), Denver, Colorado, USA
Not yet recruiting - verified July 2015

Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease

Conditions:   Myocardial Infarction;   Acute Myocardial Infarction;   Ischemic Cardiomyopathy
Intervention:   Biological: BMMSCs
Sponsors:   Academy Military Medical Science, China;   Sun Yat-sen University
Not yet recruiting - verified July 2015

Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents

Conditions:   Coronary Artery Disease;   Angina Pectoris;   Unstable Angina Pectoris;   Acute Coronary Syndrome;   Coronary Stenosis;   Coronary Restenosis
Interventions:   Device: Orsiro;   Device: Resolute Onyx
Sponsor:   Thorax Centrum Twente
Not yet recruiting - verified July 2015

XIENCE Xpedition Everolimus-Eluting Coronary Stent Post Marketing Surveillance (XIENCE Xpedition SV PMS)

Conditions:   Ischemic Heart Disease;   Angina Pectoris;   Coronary Artery Disease;   Myocardial Ischemia
Intervention:   Device: XIENCE Xpedition 2.25 mm stent
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2015

XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS)

Conditions:   Ischemic Heart Disease;   Angina Pectoris;   Coronary Artery Disease;   Coronary Artery Occlusion;   Myocardial Ischemia
Intervention:   Device: XIENCE PRIME SV Everolimus Eluting Coronary Stent
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2015

Ticagrelor vs. Prasugrel Effects on Infarct Size

Condition:   Cardiovascular Disease
Interventions:   Drug: ticagrelor;   Drug: prasugrel;   Drug: Placebo
Sponsors:   Yochai Birnbaum;   AstraZeneca
Not yet recruiting - verified July 2015

Platelet Reactivity in Acute Non-disabling Cerebrovascular Events

Conditions:   Stroke;   Ischemic Attack, Transient
Interventions:   Drug: Ticagrelor and Acetylsalicylic acid;   Drug: Clopidogrel and Acetylsalicylic acid
Sponsors:   Ministry of Science and Technology of the People´s Republic of China;   Beijing Municipal Science & Technology Commission
Not yet recruiting - verified July 2015

Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction

Condition:   Ventricular Tachycardia
Intervention:   Procedure: VT ablation
Sponsor:   Biotronik SE & Co. KG
Recruiting - verified July 2015

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Conditions:   Brain Ischemia With Non-valvular Atrial Fibrillation;   Transient Ischemic Attack With Non-valvular Atrial Fibrillation
Intervention:  
Sponsor:   University Hospital, Essen
Recruiting - verified July 2015

The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   HealthSpan Dx;   Duke University
Recruiting - verified July 2015

REducing Lung Congestion Symptoms Using thE V-wavE Shunt in Advanced Heart Failure

Condition:   Congestive Heart Failure
Intervention:   Procedure: V-Wave
Sponsor:   V-Wave Ltd
Not yet recruiting - verified July 2015

HYbrid CoronAry Revascularization in DiabeticS

Conditions:   Diabetes;   Heart Disease
Interventions:   Procedure: Treatment;   Procedure: Control
Sponsor:   Ottawa Heart Institute Research Corporation
Not yet recruiting - verified July 2015

Clinical Relevance of Microbleeds In Stroke

Conditions:   Stroke;   Atrial Fibrillation (AF);   Intracerebral Haemorrhage (ICH)
Intervention:  
Sponsor:   University College, London
Recruiting - verified July 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified July 2015

Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Device: Single lead ECG device;   Device: 7-Day Holter monitor.
Sponsors:   Leiden University Medical Center;   Medical Center Haaglanden;   Groene Hart Ziekenhuis;   Herning Hospital;   Bronovo Hospital
Not yet recruiting - verified July 2015

The Miami Heart Study at Baptist Health South Florida

Condition:   Cardiovascular Disease
Intervention:  
Sponsors:   Baptist Health South Florida;   Quest Diagnostics;   University of California, Los Angeles
Recruiting - verified July 2015

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Condition:   Heart Failure
Interventions:   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2015

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Intervention:  
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2015

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Condition:   Asthma
Interventions:   Drug: Interferon beta-1a Nebuliser solution 48 μg/mL;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography

Conditions:   Coronary Atherosclerosis;   Coronary Artery Disease;   Radiocontrast-induced Thyroid Dysfunction;   Contrast-induced Nephropathy
Interventions:   Radiation: Coronary computed tomography angiography;   Radiation: Quantitative coronary angiography
Sponsors:   Ural Medical University ;   Ural Institute of Cardiology;   De Haar Research Foundation
Enrolling by invitation - verified July 2015

Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI

Condition:   Acute Myocardial Infarction
Interventions:   Other: Allogeneic human cardiac stem cells (CSCs);   Other: Human Serum Albumin-HSA 5%
Sponsors:   Coretherapix;   European Commission;   Universitaire Ziekenhuizen Leuven;   Saint-Louis Hospital, Paris, France;   Hospital General Universitario Gregorio Marañon;   Complejo Hospitalario de Navarra;   Hospital Clínico Universitario de Valladolid;   Hospital Donostia;   Hospital Clínico Universitario de Valencia;   Hospital Universitario de Salamanca;   Hospital Universitario Virgen de la Victoria
Recruiting - verified July 2015

FFP Versus PCC in Intracranial Hemorrhage

Conditions:   Intracranial Hemorrhage, Traumatic;   Intracranial Hemorrhage, Spontaneous
Interventions:   Drug: Four Factor Prothrombin Complex Concentrate;   Biological: Fresh Frozen Plasma
Sponsor:   University of Utah
Recruiting - verified April 2015

A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: erlotinib;   Drug: BGB324
Sponsor:   BerGenBio AS
Recruiting - verified July 2015

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Recruiting - verified July 2015

MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions

Condition:   Coronary Artery Disease
Intervention:   Device: MAGIC-TOUCH Drug-eluting Balloon
Sponsor:   Scitech Produtos Medicos Ltda
Recruiting - verified July 2015

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified June 2015

The Asahi Intecc PTCA Chronic Total Occlusion Study

Conditions:   Coronary Artery Disease;   Coronary Artery Chronic Total Occlusion
Intervention:   Device: Revascularization of Coronary Artery Chronic Total Occlusion (Corsair, Gaia, Asahi Guide Wires)
Sponsors:   Asahi Intecc USA Inc;   Medpace, Inc.
Recruiting - verified July 2015

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable
Interventions:   Drug: mFOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: SBRT;   Drug: Gemcitabine
Sponsor:   NewLink Genetics Corporation
Recruiting - verified July 2015

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified July 2015

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

Conditions:   Acute Kidney Injury;   Renal Insufficiency
Intervention:   Procedure: cardiac surgery
Sponsor:   Baylor Research Institute
Recruiting - verified July 2015

The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics

Conditions:   Coronary Artery Disease;   Plaque, Atherosclerotic
Interventions:   Device: Bioresorbable Vascular Scaffold;   Drug: Optimal Medical treatment
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2015

Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis

Conditions:   Coronary Stenosis;   Cerebral Stenosis
Interventions:   Other: simultaneous coronary and cerebral intervention;   Other: staged coronary and cerebral intervention
Sponsor:   Capital Medical University
Recruiting - verified July 2015

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified July 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Condition:   Myocardial Injury
Interventions:   Drug: ticagrelor;   Drug: aspirin
Sponsors:   The Cleveland Clinic;   AstraZeneca
Recruiting - verified July 2015

Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System

Condition:   Mitral Valve Regurgitation
Intervention:   Device: Mitral valve replacement
Sponsor:   Neovasc Inc.
Recruiting - verified July 2015

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography

Conditions:   Acute Kidney Injury;   Renal Insufficiency;   Kidney Diseases
Intervention:  
Sponsors:   HealthSpan Dx;   University of North Carolina, Chapel Hill
Recruiting - verified July 2015

A Pilot Study of Transcoronary Myocardial Cooling

Condition:   Acute Myocardial Infarction
Interventions:   Other: Cohort A - Room temperature coronary perfusate;   Other: Cohort B - Cooled coronary perfusate
Sponsor:   Royal Brompton & Harefield NHS Foundation Trust
Completed - verified July 2015

Left vs Right Radial Approach in the Setting of Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction

Condition:   Transradial Approach, Primary PCI, ST-segment Elevation Myocardial Infarction
Interventions:   Procedure: Left radial approach;   Procedure: Right radial approach
Sponsor:   Capital Medical University
Completed - verified September 2014

PLATINUM Diversity

Conditions:   Atherosclerosis;   Coronary Artery Disease
Intervention:   Device: Percutaneous coronary intervention (Promus PREMIER)
Sponsor:   Boston Scientific Corporation
Recruiting - verified July 2015

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified July 2015

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Condition:   Peripheral Artery Disease (PAD)
Interventions:   Drug: Ticagrelor;   Drug: Comparator
Sponsors:   AstraZeneca;   CPC Clinical Research
Recruiting - verified July 2015

Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia

Conditions:   Acute Myocardial Infarction;   Persisting Ischemia;   No Reflow
Intervention:   Device: Intra-aortic balloon pump
Sponsors:   Lokien van Nunen;   Stichting Toegepaste Wetenschappen (project number 11052);   Maquet Cardiovascular
Recruiting - verified July 2015

Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.

Conditions:   Aortic Valve Disease;   Heart Valve Prosthesis Implantation;   Anticoagulants
Intervention:   Drug: Rivaroxaban
Sponsor:   University Hospital Inselspital, Berne
Recruiting - verified July 2015

Rivaroxaban for Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Antibody Syndrome
Intervention:   Drug: Rivaroxaban
Sponsors:   St. Joseph's Healthcare Hamilton;   Heart and Stroke Foundation of Canada;   Bayer;   Hamilton Health Sciences Corporation;   Jewish General Hospital;   University of Alberta;   The Ottawa Hospital;   Queen Elizabeth II Health Sciences Centre
Recruiting - verified July 2015

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Recruiting - verified July 2015

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2014

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Aspirin;   Drug: Ticagrelor
Sponsors:   Boca Raton Regional Hospital;   AstraZeneca
Recruiting - verified July 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified July 2015

Remote Ischemic Preconditioning of Human Myocardium

Conditions:   Coronary Artery Bypass Graft Triple Vessel;   Apoptotic DNA Damage
Interventions:   Procedure: Remote ischemic preconditioning;   Procedure: Placebo
Sponsors:   Medical University of Silesia;   National Science Centre, Poland
Recruiting - verified July 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified July 2015

Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study

Conditions:   Intradialytic Hypotension;   End Stage Renal Failure on Dialysis
Interventions:   Device: BVM-UF biofeedback;   Device: Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)
Sponsor:   University of Calgary
Completed - verified July 2015

Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative

Condition:   Acute Coronary Syndrome
Intervention:   Other: OBSERVATIONAL REGISTRY
Sponsor:   Henry Ford Health System
Completed - verified July 2015

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2015

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified July 2015

Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent

Condition:   Coronary Artery Disease
Interventions:   Device: Abbott Laboratories Xience;   Device: Biotronik Orsiro
Sponsor:   Biotronik AG
Active, not recruiting - verified July 2015

Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke

Conditions:   Brain Ischemia;   Ischemic Attack
Intervention:   Drug: Clopidogrel
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Groupe de Recherche sur la Thrombose
Recruiting - verified July 2015

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: XIENCE V EECSS;   Device: ABSORB BVS System
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2015

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

Conditions:   Angioplasty;   Cardiovascular Disease;   Chronic Coronary Occlusion;   Coronary Artery Bypass Graft (CABG);   Coronary Artery Disease;   Coronary Heart Disease;   Coronary Restenosis;   Myocardial Infarction;   Myocardial Ischemia;   Stent Thrombosis;   Vascular Disease
Intervention:   Device: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Sponsor:   Abbott Vascular
Active, not recruiting - verified July 2015

Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency

Condition:   Operating Room Scheduling
Interventions:   Other: Scheduling using historical means;   Other: Scheduling using regression modeling system
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified July 2015

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified July 2015

China Acute Myocardial Infarction Registry

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Cardiovascular Institute & Fuwai Hospital
Recruiting - verified July 2015

Brilinta DaYu Study

Condition:   Acute Coronary Syndrome
Intervention:   Drug: Ticagrelor
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2015

Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling

Conditions:   Myocardial Infarction;   Left Ventricular Remodeling;   miR-126
Intervention:  
Sponsors:   Qilu Hospital;   Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University;   Jinan Central Hospital Affiliated to Shandong University;   Shandong Provincial Hospital Affiliated to Shandong University;   The Second Hospital of Shandong University;   Ruijin Hospital;   Qingdao University;   Shandong Provincial Medical Imaging Institute of Shandong University;   The First Affiliated Hospital of Zhengzhou University;   Heze Municipal Hospital;   Jining Hospital of Traditional Chinese Medicine;   Qihe People's Hospital;   Central Hospital of Zibo;   Weihai Municipal Hospital;   Beijing Friendship Hospital Affiliated to Capital Medical University;   Affiliated Hospital of Binzhou Medical Universty;   Beijing Hospital
Completed - verified July 2015

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified July 2015

GLP-1 and Hypoglycemia

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion;   Other: Placebo Comparator: Saline Infusion
Sponsor:   University of Maryland
Recruiting - verified July 2015

Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

Conditions:   Vascular Death;   Myocardial Infarction;   Stroke;   Cardiac Surgery
Intervention:  
Sponsors:   Population Health Research Institute;   Abbott Diagnostics Division
Recruiting - verified July 2015

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children   s National Medical Center
Suspended - verified April 2015

Cardiogenesis Transmyocardial Revascularization Registry

Condition:   Class IV Angina
Intervention:  
Sponsor:   Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Completed - verified July 2015

Myocardial Infarction - Stress Prevention Intervention

Conditions:   Stress Disorders, Post-Traumatic;   Myocardial Infarction
Interventions:   Behavioral: Minimal behavioral intervention;   Behavioral: Control intervention
Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   University of Bern;   University of Zurich
Recruiting - verified July 2015

ABSORB III Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: Absorb BVS;   Device: XIENCE
Sponsor:   Abbott Vascular
Recruiting - verified July 2015

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Condition:   Peripheral Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2015

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty

Condition:   Venous Thromboembolism
Intervention:   Drug: rivaroxaban and ASA
Sponsors:   David Anderson;   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified July 2015

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2015

Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)

Conditions:   Acute Coronary Syndrome;   Angina Pectoris;   Angina, Unstable;   Myocardial Infarction;   Coronary Artery Disease;   Coronary Stenosis;   Coronary Restenosis
Interventions:   Device: Orsiro;   Device: Synergy;   Device: Resolute Integrity
Sponsor:   Cardio Research Enschede BV
Enrolling by invitation - verified July 2015

Assessment of Risk in Chronic Airways Disease Evaluation

Condition:   Chronic Obstructive Pulmonary Disease (COPD)
Intervention:  
Sponsors:   Cardiff University;   GlaxoSmithKline
Active, not recruiting - verified July 2015

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

Conditions:   Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention:   Drug: Ponatinib
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified July 2015

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Radial Strain ECHO-Guided Implantation of Cardiac Resynchronization Therapy

Condition:   Ischemic Cardiomyopathy
Intervention:   Procedure: Echo guided implantation group
Sponsors:   Sheba Medical Center;   Tel-Aviv Sourasky Medical Center;   Rabin Medical Center;   Rambam Health Care Campus;   Kaplan Medical Center;   Soroka University Medical Center;   Mayo Clinic
Recruiting - verified July 2015

Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives

Conditions:   Stroke;   Transient Ischemic Attack;   Hypertension
Intervention:   Drug: all approved antihypertensive drugs; all approved statins
Sponsors:   Istituto Auxologico Italiano;   European Society of Hypertension;   Chinese Hypertension League
Recruiting - verified July 2015

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Atorvastatin 80 mg daily;   Drug: Atorvastatin 10 mg daily
Sponsors:   Boca Raton Regional Hospital;   Pfizer
Recruiting - verified July 2015

Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)

Condition:   Myocardial Infarction
Interventions:   Procedure: Pericardial adipose pedicle (adiFLAP) transposition.;   Other: Control
Sponsor:   Germans Trias i Pujol Hospital
Completed - verified July 2015

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified July 2015

Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure

Conditions:   Transient Ischemic Attack;   Stroke
Interventions:   Device: Standard CPAP Intervention;   Behavioral: Enhanced CPAP Intervention
Sponsors:   Yale University;   National Heart, Lung, and Blood Institute (NHLBI);   Indiana University
Completed - verified November 2013

The CONFIRM Registry

Conditions:   Atherosclerosis;   Coronary Artery Disease;   Cardiovascular Disease
Intervention:  
Sponsor:   Weill Medical College of Cornell University
Enrolling by invitation - verified July 2015

Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock

Condition:   Cardiogenic Shock
Intervention:   Drug: epinephrine/norepinephrine
Sponsor:   Central Hospital, Nancy, France
Recruiting - verified July 2015

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Conditions:   Myocardial Infarction;   Segment Elevation Myocardial Infarction (STEMI)
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsor:   AstraZeneca
Completed - verified July 2015

DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population

Conditions:   Acute Coronary Syndrome;   Angina Pectoris;   Angina, Unstable;   Myocardial Infarction;   Coronary Artery Disease;   Coronary Stenosis;   Coronary Restenosis
Interventions:   Device: Resolute Integrity (Zotarolimus-eluting stent);   Device: Promus Element (Everolimus-eluting stent)
Sponsor:   Cardio Research Enschede BV
Completed - verified July 2015

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified July 2015

Statin/Vitamin D & Migraine Study

Condition:   Migraine
Interventions:   Drug: Simvastatin;   Dietary Supplement: Vitamin D;   Other: Placebo
Sponsor:   Rami Burstein
Active, not recruiting - verified July 2015

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

Condition:   Cardiovascular Disease
Interventions:   Drug: Cholecalciferol;   Drug: Placebo
Sponsor:   Creighton University
Completed - verified July 2015

Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction

Conditions:   Myocardial Infarction;   Stem Cell Transplantation;   Angioplasty, Transluminal, Percutaneous Coronary
Intervention:   Drug: Atorvastatin and mononuclear cells transplantation
Sponsor:   Cardiovascular Institute & Fuwai Hospital
Enrolling by invitation - verified July 2015

Erythropoietin in Traumatic Brain Injury (EPO-TBI)

Condition:   Traumatic Brain Injury
Interventions:   Drug: Epoetin Alfa;   Drug: Sodium Chloride 0.9%
Sponsors:   Australian and New Zealand Intensive Care Research Centre;   National Health and Medical Research Council, Australia;   Australian and New Zealand Intensive Care Society Clinical Trials Group;   Monash University
Completed - verified July 2015

Evaluation of Serial Troponin and Cardiac Multimarkers at the Point of Care in the Emergency Department

Conditions:   Acute Myocardial Infarction;   Chest Pain;   Acute Coronary Syndrome
Intervention:  
Sponsor:   Biosite
Withdrawn - verified July 2015

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Conditions:   MDS;   Immunodeficiency;   GATA2
Interventions:   Drug: Cyclophosphamide (CTX, Cytoxan);   Drug: Fludarabine(Fludara,Berlex Laboratories);   Procedure: Total Body Irradiation (TBI);   Procedure: Allogeneic HSC;   Drug: Equine Anti-Thymocyte Globulin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified July 2014

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified July 2015

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2015

MR, Myocardial Infarct and Heart Failure

Condition:   Heart Failure, Congestive
Intervention:   Procedure: PCI (percutaneous coronary intervention)
Sponsors:   Helse Stavanger HF;   Helse Vest;   Norwegian Foundation for Health and Rehabilitation;   Norwegian Heart and Lung Patient Organization;   Sparebank 1 SR-Bank Gavefond;   Amersham Health
Completed - verified June 2008

Observational Study of the Remodelling Process Following Myocardial Infarct

Conditions:   Heart Failure;   Myocardial Infarct
Intervention:  
Sponsors:   Helse Stavanger HF;   Helse Vest;   Amersham Buchler, GmbH & Co KG
Completed - verified July 2010

Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

Condition:   Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Interventions:   Drug: MK0954,   /Duration of Treatment : 5 Years;   Drug: Comparator : atenolol /Duration of Treatment : 5 Years
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

Coronary CT Angiography in Asymptomatic Diabetes Mellitus

Condition:   Diabetes Mellitus
Intervention:   Other: Imaging study, No intervention
Sponsors:   Carmel Medical Center;   European Foundation for the Study of Diabetes
Active, not recruiting - verified February 2015

A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)

Condition:   Rheumatoid Arthritis,Osteoarthritis
Interventions:   Drug: MK0663, etoricoxib;   Drug: Comparator: Diclofenac sodium
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

SHORTness of Breath In the Emergency Department (SHORTIE)

Conditions:   Acute Myocardial Infarction;   Heart Failure;   Pulmonary Embolism
Intervention:   Device: Triage Profiler S.O.B. Panel
Sponsor:   Biosite
Completed - verified July 2015

Enhancing the Secondary Prevention of Coronary Artery Disease

Conditions:   Coronary Disease;   Ischemic Heart Disease
Intervention:   Behavioral: Evidence summaries endorsed by local opinion leaders
Sponsors:   University of Alberta;   Heart and Stroke Foundation of Canada;   Alberta Heritage Foundation for Medical Research;   Pfizer
Completed - verified July 2015

Get CardioSmart

You're Invited